Impact of Sonova's Gains on Cochlear Are Unclear -- Market Talk

Dow Jones

Nov 21, 2024

0138 GMT - It isn't clear to Citi analyst Mathieu Chevrier whether Sonova's share of the hearing-implant market is at the expense of Cochlear. He tells clients in a note that Sonova called out solid market-share gains as well as overall market growth in reporting 18% on-year growth in 1H sales. The increase is well above the 10% volume growth anticipated by Cochlear over its 2025 fiscal year, but Chevrier isn't sure what is behind the difference. It could be that overall market growth is unusually strong, or that the share is shifting from Cochlear or privately held Med-EI. Citi has a neutral rating and A$305.00 target price on Cochlear shares, which are down 0.3% at A$296.99. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

November 20, 2024 20:38 ET (01:38 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2485102008"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2485102008\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2485102008?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-21 09:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485102008","market":"sh","top_or_hot":-1,"title":"Impact of Sonova's Gains on Cochlear Are Unclear -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0138 GMT - It isn't clear to Citi analyst Mathieu Chevrier whether Sonova's share of the hearing-implant market is at the expense of Cochlear. He tells clients in a note that Sonova called out solid market-share gains as well as overall market growth in reporting 18% on-year growth in 1H sales. The increase is well above the 10% volume growth anticipated by Cochlear over its 2025 fiscal year, but Chevrier isn't sure what is behind the difference. It could be that overall market growth is unusually strong, or that the share is shifting from Cochlear or privately held Med-EI. Citi has a neutral rating and A$305.00 target price on Cochlear shares, which are down 0.3% at A$296.99. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 20, 2024 20:38 ET (01:38 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Impact of Sonova's Gains on Cochlear Are Unclear -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImpact of Sonova's Gains on Cochlear Are Unclear -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-21 09:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0138 GMT - It isn't clear to Citi analyst Mathieu Chevrier whether Sonova's share of the hearing-implant market is at the expense of Cochlear. He tells clients in a note that Sonova called out solid market-share gains as well as overall market growth in reporting 18% on-year growth in 1H sales. The increase is well above the 10% volume growth anticipated by Cochlear over its 2025 fiscal year, but Chevrier isn't sure what is behind the difference. It could be that overall market growth is unusually strong, or that the share is shifting from Cochlear or privately held Med-EI. Citi has a neutral rating and A$305.00 target price on Cochlear shares, which are down 0.3% at A$296.99. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 20, 2024 20:38 ET (01:38 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7007","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2485102008","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485102008","pubTimestamp":1732153080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0138 GMT - It isn't clear to Citi analyst Mathieu Chevrier whether Sonova's share of the hearing-implant market is at the expense of Cochlear. He tells clients in a note that Sonova called out solid market-share gains as well as overall market growth in reporting 18% on-year growth in 1H sales. The increase is well above the 10% volume growth anticipated by Cochlear over its 2025 fiscal year, but Chevrier isn't sure what is behind the difference. It could be that overall market growth is unusually strong, or that the share is shifting from Cochlear or privately held Med-EI. Citi has a neutral rating and A$305.00 target price on Cochlear shares, which are down 0.3% at A$296.99. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7007":"医疗保健设备","COH.AU":"COCHLEAR LTD"},"translate_title":"索诺瓦的收益对耳蜗的影响尚不清楚——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COH.AU":0.9},"content_text":"0138 GMT - It isn't clear to Citi analyst Mathieu Chevrier whether Sonova's share of the hearing-implant market is at the expense of Cochlear. He tells clients in a note that Sonova called out solid market-share gains as well as overall market growth in reporting 18% on-year growth in 1H sales. The increase is well above the 10% volume growth anticipated by Cochlear over its 2025 fiscal year, but Chevrier isn't sure what is behind the difference. It could be that overall market growth is unusually strong, or that the share is shifting from Cochlear or privately held Med-EI. Citi has a neutral rating and A$305.00 target price on Cochlear shares, which are down 0.3% at A$296.99. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 20, 2024 20:38 ET (01:38 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}